Month: April 2026

Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award

Written by Customer Service on April 15, 2026. Posted in Public Companies.

Tokyo, Japan and Cambridge, UK, 15 April 2026 – Nxera Pharma Co. Ltd (“Nxera” or the “Company”; TSE 4565) announces that, in connection with the introduction of the Employee Stock Ownership Plan for employees residing in Japan (“J-ESOP”), as announced on 19 November 2025, it has resolved to issue new shares of the Company (the “J-ESOP Share Issuance”) as set out below. The J-ESOP Share Issuance is intended to secure the shares required for the operation of J-ESOP, including in connection with the transition to J-ESOP of certain outstanding Restricted Stock Units (“RSUs”) previously granted to employees of the Company and its wholly owned subsidiary Nxera Pharma Japan Co., Ltd. (together “Nxera Japan”) residing in Japan (“Outstanding Equity Awards”), for which the payment date or payment period has not yet arrived, and does...

CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026

Written by Customer Service on April 15, 2026. Posted in Public Companies.

AAD 2026 reinforces CLINUVEL’s expertise in dermatologyStep inside CLINUVEL’s Pavilion of Photomedicine and experience the energy of AAD 2026 through an exclusive video featuring behind-the-scenes of construction, expert insights from the CLINUVEL team and immersive visuals of guests engaging within the Pavilion.MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) — CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates. Building on momentum...

Stellantis Reports Q1 2026 Estimated Consolidated Shipments of 1.4 Million Units, +12% y-o-y

Written by Customer Service on April 15, 2026. Posted in Earnings Releases And Operating Results.

Stellantis Reports Q1 2026 Estimated Consolidated Shipments of 1.4 Million Units, +12% y-o-yGrowth in all regions, led by North America and Enlarged EuropeAMSTERDAM, April 15, 2026 – Stellantis N.V. today released its Q1 2026 estimated consolidated shipments. The term “shipments” describes the volume of vehicles delivered to dealers, distributors, or directly from the Company to retail and fleet customers, which generally drive revenue recognition. Consolidated shipments for the three months ending March 31, 2026, were an estimated 1.4 million units, up 12% y-o-y. This increase was primarily driven by Enlarged Europe and North America, and further supported by year‑over‑year shipments growth in Middle East & Africa and South America. In North America, Q1 shipments grew by approximately 54 thousand units compared to the same...

Convocation to the ordinary general shareholders’ meeting of 18 May 2026

Written by Customer Service on April 15, 2026. Posted in Earnings Releases And Operating Results.

PRESS RELEASE REGULATED INFORMATION Brussels, 15 April 2026, 7.55 am Convocation to the ordinary general shareholders’ meeting of 18 May 2026 The board of directors of Nextensa invites the shareholders to attend the ordinary general shareholders’ meeting that will be held on Monday 18 May 2026 at Maison de la Poste, Picardstraat 5 box 7, 1000 Brussels. The ordinary general meeting will commence at 4:00 PM The documents relating to these shareholders’ meeting are available from today on the website www.nextensa.eu under the heading ‘Investors’ – ‘General meetings’. For more information Michel Van Geyte | Chief Executive Officer Nextensa NV/SA | 0436.323.915 (RLE Brussels, Dutch-speaking division) Gare Maritime, Picardstraat 11, B505, 1000 Brussels +32...

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting

Written by Customer Service on April 15, 2026. Posted in Public Companies.

Nantes, France, April 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that an abstract on a novel agonist monoclonal antibody targeting FPR2, a key receptor involved in the triggering resolution of inflammation, has been selected for an oral presentation at the 2026 Annual Meeting of the American Association of Immunologists (AAI) in Boston, Massachusetts, United States (April 15-19, 2026). Aurore Morello, PhD, Chief Scientific Officer of OSE Immunotherapeutics, will unveil for the first time a novel, first‑in‑class therapeutic strategy targeting the FPR2 G‑protein–coupled receptor (GPCR). This approach aims to activate the body’s natural inflammation‑resolution...

Tryg A/S – Interim report Q1 2026

Written by Customer Service on April 15, 2026. Posted in Earnings Releases And Operating Results.

Tryg’s Supervisory Board has today approved the interim report for Q1 2026. Tryg reported a strong insurance service result of DKK 1,655m (DKK 1,540m) and a combined ratio of 84.0% (84.2%) in Q1 2026. The higher insurance service result was supported by an underlying claims ratio improvement of 40 basis points (up from 30 bps), including solid trends in Norway and a premium growth of 3.5% (3.7%) in local currencies. The investment result was DKK 2m (DKK 320m), showcasing the strength of Tryg’s low-risk investment approach in volatile markets. Pre-tax profit was DKK 1,276m (DKK 1,491m) and profit after tax was DKK 958m (DKK 1,118m). Ordinary dividend of DKK 2.15 (DKK 2.05) per share for the year is an increase of around 5% from the previous year. The reported solvency ratio at the end of Q1 2026 was 192% (196% Q4 2025), supportive...

Aegon to sell Aegon UK to Standard Life for a total consideration of GBP 2.0 billion

Written by Customer Service on April 15, 2026. Posted in Mergers And Acquisitions.

Schiphol, April 15, 2026Transaction marks the completion of the strategic review of Aegon UK, further supporting Aegon in its ambition to become a leading US life insurance and retirement group The proceeds are valued at GBP 2.0 billion and consist of a shareholding of 15.3% (181.1 million shares) in Standard Life plc (Standard Life)1 and a cash amount of GBP 0.75 billion. Any remittances taken out of Aegon UK between the signing and closing of the transaction will be deducted from the GBP 0.75 billion cash amount Total consideration equivalent to 14.2x 2025 operating result after tax and 1.9x 2025 IFRS Shareholder’s equity2 The cash received from the transaction, minus the value of the remittances that were expected to be received from Aegon UK between the signing and the closing of the transaction, is expected to be used for a combination...

ASML reports €8.8 billion total net sales and €2.8 billion net income in Q1 2026

Written by Customer Service on April 15, 2026. Posted in Earnings Releases And Operating Results.

ASML reports €8.8 billion total net sales and €2.8 billion net income in Q1 2026ASML now expects 2026 total net sales to be between €36 billion and €40 billion, with a gross margin between 51% and 53% VELDHOVEN, the Netherlands, April 15, 2026 – Today, ASML Holding NV (ASML) has published its 2026 first-quarter results. Q1 total net sales of €8.8 billion, gross margin of 53.0%, net income of €2.8 billion ASML expects Q2 2026 total net sales between €8.4 billion and €9.0 billion, and a gross margin between 51% and 52% ASML now expects 2026 total net sales to be between €36 billion and €40 billion, with a gross margin between 51% and 53%(Figures in millions of euros unless otherwise indicated) Q4 2025 Q1 2026Total net sales 9,718 8,767…of which Installed Base Management sales1 2,134 2,488 New lithography...

Abcourt Presents Operations Update for the Quarter ended March 31st, 2026, in the Development of the Sleeping Giant Mine

Written by Customer Service on April 15, 2026. Posted in Public Companies.

ROUYN-NORANDA, Quebec, April 15, 2026 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to provide an update on development work completed in the quarter ended March 31st, 2026, at the Sleeping Giant Mine, located in the Eeyou Istchee region of Quebec. In March, Abcourt continued hiring and training miners. Nine new employees joined the Abcourt team, bringing the total to 143 employees. The plan is to bring the total workforce to 190 employees in the coming months. Operation Highlights Q1 2025/09/30 Q2 2025/12/31 Q3 2026/03/31 YTDDiamond Drilling (m) 6,467 4,572 7,153 18,192Underground Rehabilitation (m) 1,703 903 455 3,061Underground Development (m) 71 290 307 669Tonnes Milled (tonnes) 3,511 5,652 7,445 16,608Mill Head Grade (g/t) 5.9 6.2 5.2 5.7Ounces...

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

Written by Customer Service on April 15, 2026. Posted in Public Companies.

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) —Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections. Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026. BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026. ESCMID is the premier annual congress of the European Society of Clinical Microbiology and Infectious Diseases. It takes place from April 17 – 21, 2026 in Munich, Germany.BioVersys AG (SIX: BIOV),...

Month: April 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals